Symbol not found

NASDAQ:ALXO   00:00AM GMT
0.00
0.00 (0.00%)
Products

Alx Oncology Receives U.S. FDA Orphan Drug Designation For Evorpacept For The Treatment Of Patients With Acute Myeloid Leukemia

Published: 06/29/2022 11:20 GMT
Alx Oncology Holdings Inc (ALXO) - Alx Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients With Acute Myeloid Leukemia.